Fulcrum Therapeutics Sees Unusually High Options Volume (NASDAQ:FULC)

Fulcrum Therapeutics, Inc. (NASDAQ:FULCGet Free Report) was the recipient of unusually large options trading activity on Monday. Traders bought 21,436 call options on the company. This represents an increase of 9,180% compared to the average volume of 231 call options.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on FULC shares. Royal Bank of Canada started coverage on shares of Fulcrum Therapeutics in a report on Wednesday, March 13th. They set an “outperform” rating and a $14.00 target price on the stock. Piper Sandler increased their target price on shares of Fulcrum Therapeutics from $13.00 to $15.00 and gave the stock an “overweight” rating in a report on Wednesday, February 28th. HC Wainwright increased their price target on shares of Fulcrum Therapeutics from $14.00 to $17.00 and gave the company a “buy” rating in a research report on Wednesday, February 28th. Finally, The Goldman Sachs Group increased their price target on shares of Fulcrum Therapeutics from $5.00 to $6.00 and gave the company a “neutral” rating in a research report on Thursday, January 25th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $13.17.

Check Out Our Latest Research Report on FULC

Insider Transactions at Fulcrum Therapeutics

In other news, VP Greg Tourangeau sold 4,884 shares of the company’s stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $11.72, for a total value of $57,240.48. Following the transaction, the vice president now directly owns 11,807 shares in the company, valued at $138,378.04. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 2.50% of the company’s stock.

Hedge Funds Weigh In On Fulcrum Therapeutics

A number of institutional investors have recently bought and sold shares of the business. FMR LLC raised its position in Fulcrum Therapeutics by 17.6% during the 1st quarter. FMR LLC now owns 6,156,328 shares of the company’s stock worth $17,546,000 after buying an additional 922,603 shares during the last quarter. Suvretta Capital Management LLC grew its stake in Fulcrum Therapeutics by 10.5% in the 2nd quarter. Suvretta Capital Management LLC now owns 5,718,881 shares of the company’s stock valued at $18,872,000 after acquiring an additional 541,171 shares during the period. Cowen AND Company LLC grew its stake in Fulcrum Therapeutics by 38.2% in the 3rd quarter. Cowen AND Company LLC now owns 4,308,359 shares of the company’s stock valued at $19,129,000 after acquiring an additional 1,191,363 shares during the period. BlackRock Inc. grew its stake in Fulcrum Therapeutics by 28.0% in the 1st quarter. BlackRock Inc. now owns 4,183,738 shares of the company’s stock valued at $11,924,000 after acquiring an additional 914,747 shares during the period. Finally, Vanguard Group Inc. grew its stake in Fulcrum Therapeutics by 0.7% in the 3rd quarter. Vanguard Group Inc. now owns 2,643,195 shares of the company’s stock valued at $11,736,000 after acquiring an additional 17,166 shares during the period. 89.83% of the stock is owned by hedge funds and other institutional investors.

Fulcrum Therapeutics Stock Down 2.5 %

Shares of Fulcrum Therapeutics stock opened at $9.43 on Tuesday. The firm has a market capitalization of $584.09 million, a P/E ratio of -5.97 and a beta of 2.31. The company has a 50 day moving average price of $9.14 and a 200 day moving average price of $6.34. Fulcrum Therapeutics has a 52 week low of $2.25 and a 52 week high of $13.70.

Fulcrum Therapeutics (NASDAQ:FULCGet Free Report) last announced its quarterly earnings data on Tuesday, February 27th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.04. The firm had revenue of $0.87 million during the quarter, compared to analyst estimates of $0.65 million. Fulcrum Therapeutics had a negative net margin of 3,470.05% and a negative return on equity of 36.65%. As a group, research analysts anticipate that Fulcrum Therapeutics will post -1.76 earnings per share for the current fiscal year.

Fulcrum Therapeutics Company Profile

(Get Free Report)

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia is under phase I clinical trial.

Featured Stories

Receive News & Ratings for Fulcrum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulcrum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.